Abstract library

388 results for "VIPoma syndrome".
#244 Challenges in the Management of VIPoma Patients
Introduction: VIPomas are a rare neuroendocrine tumor (NET). 90% are pancreatic. 40-70% are metastatic at presentation. The VIPoma syndrome is characterized by secretory diarrhoea, hypokalaemia and achlorhydria.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Fatima El-Khouly
#1261 Emergency Therapy for Liver Metastases from Advanced VIPoma: Surgery or Transarterial Chemoembolization
Introduction: VIPoma is a rare neuroendocrine tumor (NET) with a high potential to develop hepatic metastases and poor prognosis. The primitive tumor is non-symptomatic and usually localized within the pancreas. Liver metastasis drove the prognosis and induced profuse watery diarrhea or renal failure.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Johann Dréanic
#1143 Ectopic Cushing’s Syndrome (ECS) in Patients with Neuroendocrine Neoplasms
Introduction: Ectopic Cushing syndrome (ECS) has been described in patients with neuroendocrine neoplasms (NENs)
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Krystallenia Alexandraki
Keywords: ECS
#1704 Diffusion Weighted Imaging as a Screening Tool in the Detection and Monitoring of Pancreatic Neuroendocrine Tumours in Patients with Familial Cancer Syndromes.
Introduction: Pancreatic neuroendocrine tumours (PNETs) occur at a higher frequency and at a younger age in patients with certain genetic conditions e.g. Von Hippel Lindau and Multiple Endocrine Neoplasia type 1. Screening for early detection and monitoring growth rates of PNETs in these high risk patients is vital in their management. MRI has emerged as the gold standard for imaging the pancreas for the detection of PNETs and diffusion weighted imaging (DWI) has become an invaluable adjunct.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Carys Jenkins
Authors: Jenkins C, Thomas W, Parry C, Khan M, ...
Keywords: PNET, MRI, VHL, MEN1
#1357 Type 1 Gastric Neuroendocrine Tumor with SAPHO Syndrome Effectively Treated by Octreotide:A Case Report
Introduction: Type 1 gastric neuroendocrine tumor (gNET) which is associated with chronic atrophic gastritis type A can be treated with SSA for the recurrence. SAPHO syndrome characterized by synovitis, acne, pustulosis, hyperostosis and osteitis is a kind of rare aseptic inflammation, which is thought to be related with abnormal autoimmune. Presently, there is no satisfied treatment for this illness.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Dou D, Wu Y T, Tan H, ...
Keywords: gnet, SAPHO syndrome, SSA
#506 Paraneoplastic Neurological Syndrome in a Patient with a Pancreatic Well-Differentiated Endocrine Tumor
Introduction: Few studies report the association of neurological syndromes with a carcinoid, the majority being small-cell lung cancer.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD, PhD Maria Pia Brizzi
#1363 Efficacy of Lutetium-177 DOTA Octreotate Peptide Receptor Radionuclide Therapy in Patients with Advanced Neuroendocrine Tumours and Carcinoid Syndrome Refractory to Somatostatin Analogues
Introduction: Somatostatin Analogues (SSAs) are considered the gold standard treatment in Neuroendocrine Tumours (NETs) and carcinoid syndrome.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Apostolos Koffas
#35 Primary Hyperparathyroidism in patients with gastric carcinoid Tumors type-1: an unusual coexistence
Introduction: Although a number of familiar endocrine syndromes are associated with primary hyperparathyroidism (PHP), there is no information regarding its prevalence in other sporadic neuroendocrine diseases.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Dimitrios Thomas
#59 Incidence and clinical significance of adrenal masses in patients with gastrenteropancreatic neuroendocrine tumors
Introduction: The widespread application of modern imaging modalities, mainly computerized tomography (CT) and magnetic resonance imaging (MRI), has revealed a 2-3% incidence of inadvertently discovered adrenal masses, the majority of which are non-functioning benign adrenal adenomas. In the presence of a known malignancy, such lesions have a more than 30% incidence of being metastases. As patients with gastrenteropancreatic neuroendocrine tumors (GEP-NETS) have mainly well-differentiated and slow-growing tumors and are subject to routine abdominal imaging for disease staging or during follow-up, it is important to study the incidence and significance of such lesions based on the recently introduced TNM classification system.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Georgios Kanakis
#86 Structure of complications in acromegalic patients at a single institute
Introduction: Acromegaly leads to reduced life expectancy, with an increase in the mortality rate. From several retrospective cohort studies, the predominant outcome is serum growth hormone (GH) concentration. Other factors associated with increased mortality include duration of symptoms prior to diagnosis, duration of disease, older age at diagnosis and the presence of cardiovascular disease, diabetes mellitus (DM) and hypertension at diagnosis.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: OKH OKSANA OLEGOVNA KHYZHNYAK